Malignant Prostate Neoplasm

From 14 prostate cancer patients (88%) who had a response to olaparib, 7 patients had BRCA2 loss (4 with biallelic somatic loss, and 3 with germline mutations), 4 of 5 with had ATM aberrations and one… (full text at CIViC)

PMID 26510020 · Mateo et al., 2015 · Open in CIViC

This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

In a phase 2 trial, patients with metastatic castration-resistant prostate cancer harboring DNA damage repair (DDR) gene aberrations were treated with olaparib. In gene testing, samples from tumor tis… (full text at CIViC)

Open in CIViC

This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

In a study of 107 prostate adenocarcinomas, those with either hemi- or homozygous deletions of PTEN (as determined by interphase FISH) have shorter biochemical recurence-free survival than those witho… (full text at CIViC)

PMID 17700571 · Yoshimoto et al., 2007 · Open in CIViC

PTEN Loss (by FISH) is associated with poorer prognosis in patients with prostate cancer.

PMID 17700571 · Yoshimoto et al., 2007 · Open in CIViC

Multicenter, international, phase Ib/II trial evaluating ipatasertib 400 mg, ipatasertib 200 mg, or placebo, with abiraterone 1,000 mg orally. Combined blockade with abiraterone and ipatasertib showed… (full text at CIViC)

PMID 30037818 · de Bono et al., 2019 · Open in CIViC

Phase 3 trial compared ipatasertib plus abiraterone and prednisolone or placebo plus abiraterone and prednisolone for patients with castration resistant prostate cancer. Primary endpoint was radiograp… (full text at CIViC)

PMID 34246347 · Sweeney et al., 2021 · Open in CIViC

Castrated mice bearing androgen-sensitive human prostate adenocarcinomas (LNCaP tumors) were treated with PI3K inhibitors (AZD8186, BYL719) and an androgen receptor inhibitor (MDV3100). Mice treated … (full text at CIViC)

PMID 25544636 · Schwartz et al., 2015 · Open in CIViC

This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

One of the goals of this study was to find the local failure rates in tumors for patients with Prostate Cancer. The failure rates for the first and second year for patients who lost SMAD4 expression w… (full text at CIViC)

PMID 29329157 · Herman et al., 2018 · Open in CIViC

The under expression of SMAD4 resulted in a higher Gleason score and a higher level of preoperative prostate specific antigen (PSA). It is considered for low levels of PSA to be normal. Patients with … (full text at CIViC)

PMID 24272204 · Zhang et al., 2014 · Open in CIViC

STK11-deficient cells were sensitive to treatment with MAPK11 inhibitor SB202190.

PMID 26391455 · Grossi et al., 2015 · Open in CIViC

68 Caucasian men with metastatic castration resistant prostate cancer underwent treatment with abiraterone acetate. 832 single nucleotide polymorphisms (SNPs, Illumina OmniExpress) of 61 candidate gen… (full text at CIViC)

PMID 27150425 · Agarwal et al., 2016 · Open in CIViC

Trop2 (TACSTD2) levels were evaluated from 234 patients who underwent radical prostatectomy. These levels were found to be significantly correlated with recurrence (P=0.01), with 58 patients displayin… (full text at CIViC)

PMID 31932422 · Hsu et al., 2020 · Open in CIViC

Genes not previously reported to be significantly mutated in PCa, such as cell division cycle 27 homolog (Saccharomyces cerevisiae) (CDC27), myeloid/lymphoid or mixed-lineage leukemia 3 (MLL3), lysine… (full text at CIViC)

PMID 23265383 · Lindberg et al., 2013 · Open in CIViC

TMPRSS2/ERG gene fusion was observed in 23 of 29 (79%) of prostate carcinoma samples, and 90% of ERG expression positive prostate carcinoma samples.

PMID 16254181 · Tomlins et al., 2005 · Open in CIViC

TMPRSS2-ETV1 fusions are recurrent in prostate cancers.

PMID 16254181 · Tomlins et al., 2005 · Open in CIViC

Non-invasive detection of multiple TMPRSS2:ERG fusion mutations in urine samples of patients with prostate cancer. Rapid 60 minute screening using DNA ligase and isothermal amplification to detect m… (full text at CIViC)

PMID 27865106 · Koo et al., 2017 · Open in CIViC

Prostate cancer cell lines over-expressing TSPYL1 P62S had similar levels of cell proliferation as control cells normally expressing TSPYL1 wildtype when treated with abiraterone. Authors note that TS… (full text at CIViC)

PMID 29027195 · Qin et al., 2018 · Open in CIViC

In a prospective clinical trial, 87 metastatic castration resistant prostate cancer (mCRPC) patients treated with abiraterone acetate/prednisone (AA/P) showed that TSPYL1 R62S (NC_000006.11:g.11660081… (full text at CIViC)

PMID 29027195 · Qin et al., 2018 · Open in CIViC

Case report of a patient with metastatic prostate cancer and underexpression of TYMS who showed a nonspecified response to pemetrexed for at least 4 months.

PMID 24782778 · Russell et al., 2014 · Open in CIViC